Nasal Sprays & Suspensions
Why CDMO Experience Matters for Complex Liquid Drug Products
When it comes to nasal spray drug products, the formulation is everything. Most nasal sprays are either solutions or suspensions. In a solution, the active pharmaceutical ingredient (API) is fully dissolved in liquid — producing a clear and uniform dose with each spray. A suspension, by contrast, involves fine particles dispersed throughout a liquid, which presents a greater challenge in formulation, manufacturing, and quality control.
For pharmaceutical companies, the difference between the two has major implications for development, scale-up, and commercial success — particularly when working with a contract manufacturing partner.
What Makes Suspensions Demanding?
Suspensions require precise formulation and handling. Even small inconsistencies can impact dose delivery, spray performance, or long-term product stability. Key technical considerations include controlling particle size distribution, maintaining physical stability throughout the product’s shelf life, and applying robust analytical methods to ensure uniformity and dosing accuracy.
It’s also essential to ensure compatibility with sterile or non-sterile fill-finish environments, while optimising nasal spray pump performance and spray characteristics.
That’s why CDMOs working with nasal suspensions must not only offer liquid contract manufacturing capabilities, but also bring deep expertise in nasal spray development, quality testing, and regulatory compliance.
A Shifting Landscape — And the Need for Speed
The demand for nasal spray therapies is growing, both in prescription markets (e.g. for CNS, pain, allergy, and hormone therapies) and in OTC formulations. At the same time, the complexity of these products and regulatory expectations around consistency, sterility, and performance continue to rise.
This creates a challenge: pharmaceutical companies need agile, experienced CDMO partners who can adapt quickly, validate reliably, and scale efficiently. Yet many contract manufacturers lack the specialized fill-finish capabilities, equipment, or regulatory track record to support these technically demanding nasal formats — particularly for suspensions.
Why Curida is a Trusted Nasal Spray CDMO
With over 10 years of experience supporting nasal spray products—including both solutions and suspensions—Curida offers end-to-end services that take products from development through to full-scale production. As a European CDMO, we specialise in sterile and non-sterile fill-finish for liquid pharmaceuticals, in-house analytical testing and method transfer, and have deep expertise in nasal spray formulation, device integration, and packaging. Our approach ensures reliable batch control and tech transfer support, along with extensive experience handling controlled drugs.
Built on flexibility, our liquid contract manufacturing model supports both clinical and commercial volumes.
We scale efficiently to meet growing demand—without ever compromising on quality, documentation, or delivery timelines.
Ready to Develop or Scale a Nasal Spray?
Whether you’re working on a new nasal spray solution or suspension or looking to improve and scale an existing product, Curida offers the specialized skills and manufacturing infrastructure needed to succeed.
Let’s bring your nasal spray product to market — faster, safer, and with confidence.
Get in touch today.